BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 15919445)

  • 1. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy.
    Nakamura Y; Takeuchi H; Okuyama K; Akashi T; Jojima Y; Konno O; Akashi I; Hama K; Iwahori T; Ashizawa T; Hirano T; Oka K; Matsuno N; Nagao T
    Transplant Proc; 2005 May; 37(4):1725-7. PubMed ID: 15919445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters.
    Takeuchi H; Okuyama K; Konno O; Jojima Y; Akashi I; Nakamura Y; Iwamoto H; Hama K; Iwahori T; Uchiyama M; Ashizawa T; Matsuno N; Nagao T; Hirano T; Oka K
    Transplant Proc; 2005 May; 37(4):1745-7. PubMed ID: 15919452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence of different pharmacokinetics between cyclosporine and tacrolimus in renal transplant recipients: why cyclosporine is monitored by C2 level and tacrolimus by trough level.
    Takeuchi H; Matsuno N; Hirano T; Toraishi T; Konno O; Nakamura Y; Iwamoto H; Hama K; Unezaki S; Nagao T
    Transplant Proc; 2008 Sep; 40(7):2240-2. PubMed ID: 18790203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral.
    Wang CH; Ko WJ; Chou NK; Wang SS
    Transplant Proc; 2004 Oct; 36(8):2386-7. PubMed ID: 15561257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence of different pharmacokinetics including relationship among AUC, peak, and trough levels between cyclosporine and tacrolimus in renal transplant recipients using new pharmacokinetic parameter--why cyclosporine is monitored by C(2) level and tacrolimus by trough level--.
    Takeuchi H; Matsuno N; Senuma K; Hirano T; Yokoyama T; Taira S; Kihara Y; Kuzuoka K; Konno O; Jojima Y; Mejit A; Akashi I; Nakamura Y; Iwamoto H; Hama K; Iwahori T; Ashizawa T; Nagao T; Toraishi T; Okuyama K; Oka K; Unezaki S
    Biol Pharm Bull; 2008 Jan; 31(1):90-4. PubMed ID: 18175948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
    Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH
    Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
    Schultz KR; Nevill TJ; Balshaw RF; Toze CL; Corr T; Currie CJ; Strong DK; Keown PA
    Bone Marrow Transplant; 2000 Sep; 26(5):545-51. PubMed ID: 11019845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of area under the whole blood concentration versus time curve after first intravenous cyclosporine dose in children undergoing hematopoietic stem cell transplant: limited sampling strategies.
    Sibbald C; Seto W; Taylor T; Saunders EF; Doyle J; Dupuis LL
    Ther Drug Monit; 2008 Aug; 30(4):434-8. PubMed ID: 18641547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation.
    Kimura S; Oshima K; Okuda S; Sato K; Sato M; Terasako K; Nakasone H; Kako S; Yamazaki R; Tanaka Y; Tanihara A; Higuchi T; Nishida J; Kanda Y
    Bone Marrow Transplant; 2010 Jun; 45(6):1088-94. PubMed ID: 19898510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal initial dose of orally administered cyclosporine following intravenous cyclosporine therapy.
    Ishizawa T; Sugawara Y; Ikeda M; Hasegawa K; Makuuchi M
    Transplant Proc; 2005 Dec; 37(10):4370-2. PubMed ID: 16387123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achieving adequate cyclosporine exposure in liver transplant recipients: a novel strategy for monitoring and dosing using intravenous therapy.
    Lück R; Böger J; Kuse E; Klempnauer J; Nashan B
    Liver Transpl; 2004 May; 10(5):686-91. PubMed ID: 15108262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic monitoring of cyclosporine in kidney transplantation: the Halifax experience.
    Singh D; Kiberd B; Belitsky P; Fraser A; Balbontin F; Lawen J
    Transplant Proc; 2004 Mar; 36(2 Suppl):414S-419S. PubMed ID: 15041377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of cyclosporine A at a high-peak concentration of twice-daily infusion and oral administration in allogeneic haematopoietic stem cell transplantation.
    Inoue Y; Saito T; Ogawa K; Nishio Y; Kosugi S; Suzuki Y; Shibuya Y; Kato M; Takahashi M; Miura I
    J Clin Pharm Ther; 2011 Aug; 36(4):518-24. PubMed ID: 21105879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of living donor liver transplant patients using twice-daily 4-hour intravenous cyclosporine therapy.
    Sato K; Iwane T; Sekiguchi S; Nakamura A; Akamatsu Y; Kawagishi N; Miyagi S; Takeda I; Sato A; Fujimori K; Satomi S
    Transplant Proc; 2009; 41(1):229-32. PubMed ID: 19249521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of cyclosporine a conversion from twice-daily infusion to oral administration in allogeneic hematopoietic stem cell transplantation.
    Inoue Y; Saito T; Ogawa K; Nishio Y; Kosugi S; Suzuki Y; Kato M; Sakai H; Takahashi M; Miura I
    Am J Ther; 2014; 21(5):377-84. PubMed ID: 23011175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of the therapeutic drug monitoring of cyclosporine.
    Citterio F
    Transplant Proc; 2004 Mar; 36(2 Suppl):420S-425S. PubMed ID: 15041378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of initial i.v. CYA dosage to achieve target AUC values in pediatric hematopoietic stem cell transplant patients.
    Jin M; Seto W; Taylor T; Saunders EF; Doyle J; Dupuis LL
    Bone Marrow Transplant; 2008 Oct; 42(7):455-9. PubMed ID: 18622423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circadian and time-dependent variability in tacrolimus pharmacokinetics.
    Park SI; Felipe CR; Pinheiro-Machado PG; Garcia R; Tedesco-Silva H; Medina-Pestana JO
    Fundam Clin Pharmacol; 2007 Apr; 21(2):191-7. PubMed ID: 17391292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The area under the concentration-time curve versus trough and peak blood level monitoring in renal transplant recipients on cyclosporine.
    Halim MA; Nampoory MR; Johny KV; Donia F; Hamid MH; Said T; Nair MP; Mansour M; Al-Muzairai I; Samhan M; Al-Mousawi M
    Transplant Proc; 2005 Sep; 37(7):3019-21. PubMed ID: 16213291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of oral versus sublingual administration of tacrolimus in adult liver transplant recipients.
    Nasiri-Toosi Z; Dashti-Khavidaki S; Nasiri-Toosi M; Khalili H; Jafarian A; Irajian H; Abdollahi A; Sadrai S
    Exp Clin Transplant; 2012 Dec; 10(6):586-91. PubMed ID: 22770208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.